Chicago – October 28, 2026 -- EVERSANA has acquired London-based health economics and outcomes research (HEOR) technology company Estima Scientific, adding generative-AI tools for economic modeling, systematic literature reviews and network meta-analysis to its market access offering. Financial terms were not disclosed.

AUSTIN – October 28, 2026 -- Genprex (NASDAQ: GNPX) will present research on the TUSC2 gene, the therapeutic payload of its lead lung cancer candidate REQORSA, in mitochondrial biology and cellular aging at the Gerontological Society of America (GSA) 2026 Annual Scientific Meeting, widening the scientific case for the asset beyond oncology.

SEOUL – October 28, 2026 -- Korean biotechnology company CELSET INC. has launched SOLTOX, a botulinum toxin type A brand, in 100 Unit and 200 Unit formulations for international medical aesthetics markets.

SOLTOX combines a 900 kDa complex with a freeze-dried dosage form

The product is built on three technical characteristics: a 900 kDa toxin complex, a lyophilized powder format and an advanced purification process. The powder is reconstituted before administration by qualified medical professionals, in line with product labeling and local requirements.

MADRID – October 28, 2026 -- Hengrui Pharma presented a record 64 oncology studies at the ESMO Congress 2026 in Madrid. Innovative oncology medicines generated 81.02% of the company's innovative medicine sales revenue in 2025.

Hangzhou – October 28, 2026 -- Lynk Pharmaceuticals reported that its oral JAK1 inhibitor zemprocitinib sustained a 91.8% ACR20 response rate at Week 76 in rheumatoid arthritis patients who had failed or could not tolerate biologic therapy, with no new safety signals in the pivotal Phase III trial.

TOKYO – October 28, 2026 -- Astellas Pharma Inc. has secured an exclusive option on a worldwide license to Audax Biosciences' immuno-oncology candidate DAX-044 in a transaction worth up to US$1.34 billion, excluding royalties.

Audax receives US$285 million up front and on option exercise

Audax will receive US$285 million in combined up-front and option-exercise payments. It is also eligible for development and commercial milestones of up to US$1.05 billion, plus tiered double-digit royalties on worldwide net sales if DAX-044 is approved.

Thousand Oaks – October 28, 2026 -- Amgen's Board of Directors declared a fourth-quarter 2026 dividend of $2.52 per share, the company (NASDAQ: AMGN) announced.

Amgen sets December 11 payment date for Q4 dividend

The dividend will be paid on December 11, 2026, to all stockholders of record as of the close of business on November 20, 2026.

SAN FRANCISCO – October 28, 2026 -- Nektar Therapeutics (Nasdaq: NKTR) will report third-quarter 2026 financial results for the period ended September 30 on Thursday, November 12, 2026, after U.S. markets close.

CEO Howard Robin to host 5:00 p.m. ET results call

President and Chief Executive Officer Howard Robin will lead a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to review the quarter.

Thousand Oaks – October 28, 2026 -- Amgen's dazodalibep reduced systemic disease activity in Sjögren's disease patients by 5.6 points on the ESSDAI scale at Week 48 in the Phase 3 OASIZ-301 trial, against 3.8 points for placebo. The company will present the late-breaking data at the American College of Rheumatology (ACR) Convergence 2026.

LOUISVILLE – October 28, 2026 -- US WorldMeds Ventures, LLC has acquired Orbus Therapeutics, Inc., adding a late-stage eflornithine program for recurrent Grade 3 astrocytoma. In a prespecified subset of the Phase 3 STELLAR study, patients with IDH-mutant disease reached median overall survival of 34.9 months, versus 23.5 months on lomustine alone.